The majority of drugs fail in the later stages of the drug development pipeline and in clinical trials because of insufficient predictivity of cell models used to screen drug candidates. Organoids show great promise as a game-changer in disease modeling and drug screening since they better resemble tissue structure and functionality, and show more predictive response to drugs. However, challenges associated with using organoids, such as assay complexity, reproducibility, and the ability to scale up have limited their widespread adoption as a primary screening method in drug discovery.
To alleviate the bottlenecks that come with labor-intensive manual protocols, we developed the CellXpress.ai™ Automated Cell Culture System. This instrument automates the entire 3D organoid or 2D cell culture workflow: providing media exchange, plating, passaging, organoid monitoring, end-point assay execution, and complex image analysis. It contains functional components including an automated imager, liquid handler, and incubator, connected by AI- powered software. The development of cell cultures is monitored by periodic imaging and analysis, which can trigger automatic decisions to initiate passaging, end-point assays, or troubleshooting steps. We will present the results from the automation of several commonly used 3D organoid protocols, as well as 2D assays.
.png)
.jpg "Oksana Sirenko, PhD (she/her/hers) photo")
